News tagged with erlotinib
Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head ...
Jan 26, 2012 |
not rated yet |
0
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...
Jul 05, 2011 |
not rated yet |
0
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at ...
Jul 05, 2011 |
not rated yet |
0
A drug combination extends survival in refractory lung cancer patients
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 02, 2011 |
not rated yet |
0
Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Jun 01, 2011 |
not rated yet |
0
Asian lung cancer patient survival exceeds Caucasians' on multiple regimens
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...
Jun 01, 2011 |
not rated yet |
0
Erlotinib effective and with fewer side-effects after first-line treatment
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results ...
Feb 26, 2011 |
not rated yet |
0
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
Feb 25, 2011 |
5 / 5 (1) |
0
Personalized molecular therapy shows promising results for people with advanced lung cancer
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium ...
Dec 09, 2010 |
not rated yet |
0
Assessing positive outcomes of phase III trials
Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in ...
Dec 03, 2010 |
not rated yet |
0
Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) ...
Nov 17, 2010 |
5 / 5 (1) |
0
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, ...
Oct 12, 2010 |
5 / 5 (1) |
1
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a ...
Oct 09, 2010 |
not rated yet |
0
TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, revers ...
Oct 01, 2010 |
not rated yet |
0
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted ...
Sep 28, 2010 |
not rated yet |
0
Erlotinib
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.
For more information about Erlotinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
